Alastair Riddell

CXR Biosciences Ltd. provides drug development solutions and investigative toxicology services. Its drug development solutions include bioavailability, patient response variation, drug and drug interactions, drug reactions, toxicity, reactive metabolites, customized assay development, and anticancer drug development services. The firm serves pharmaceutical, biotech, agrochemical, consumer product, and fine chemical industries. The company was founded by Clifford Roy Elcombe and Roland Charles Wolf in December 2001 and is headquartered in Dundee, the United Kingdom.

Bioseek UK Ltd. manufactures biotechnology products, drug discovery tools, and pharmaceuticals. Bioseek UK Ltd. is based in London, UK.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Sareum Ltd. provides drug discovery services for treatment of cancer. The company develops robust pipeline of novel small molecule cancer drug candidates for partnering with pharmaceutical companies. Sareum is headquartered in Cambridge, UK

Asset Realisation Co. Plc is in Members Voluntary Liquidation and the company's affairs are subsequently being administered by Samantha Keen and Ian Carr of Grant Thornton UK LLP as joint liquidators. The company was previously called Stem Cell Sciences Plc but changed its name after selling its operating assets to Stem Cells, Inc. The company is developing and applying stem cells and stem cell technologies in biopharmaceutical research and cell-based therapies. The company owns a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. These include technologies to permit the generation of purified stem cells and their differentiated progeny for use in genetic, pharmacological and toxilogical screens. Moreover, these technologies can be utilized to provide pure populations of appropriate cell types for transplantation therapies. The operations are carried out through its four business units namely SC Proven, SC Licensing, SC Services and SC Therapy. The company operates in the United Kingdom and Australia.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

DefiniGEN Ltd. provides human cell products to the drug discovery sector. Its services include iPSC Differentiation, Gene Editing, CRISPR Modeling and Patient Derived Models. The firm products include Hepatocytes, Intestinal and Pancreatic. The company was founded in April 2012 by Candy Hsin-Hua Cho, Nicolas R. F. Hannan, Roger A. Pedersen and Tamir Rashid and is headquartered in Cambridge, the United Kingdom.

Skyline Vet Pharma, Inc. engages in the manufacture of veterinary pharmaceutical products. The company was founded by Serge R. Martinod and George F. Murphy and is headquartered in Groton, CT.

Nemesis Biosciences Ltd. develops and commercializes therapeutic agents that resurrect the antibiotic sensitivity of currently resistant microbial pathogens. Its symbiotics kill pathogenic microorganisms directly and/or make them susceptible to currently existing antibiotics. The company was founded by Frank Massam, Conrad Lichtenstein and Gi Mikawa in March 2014 and is headquartered in Cambridge, the United Kingdom.

South West Peninsula AHSN Ltd. is a British company that is part of the AHSN Network, which aims to transform the prevention of cardiovascular disease through a national blood pressure optimization program. The private company is based in Exeter, UK. The company's purpose is to transform lives through health and care innovation. The CEO of the company is Richard Watson.

Surface Therapeutics Ltd. develops novel drugs & diagnostics for asthma and epithelial diseases. It also develops new pharmaceutical products for the treatment of inflammatory epithelial diseases with a focus on the skin and lungs. The company was founded in 2004 and is headquartered in Abingdon, LO.